. 2017 Jan 24;10:31. doi: 10.1186/s13045-016-0389-4

Table 5.

Multivariate analyses

	Chronic GVHD		NRM		Relapse		LFS		OS		GRFS
	p value	OR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)
In vivo T cell depletion	0.0001	0.46 (0.31–0.68)	0.094	0.59 (0.32–1.09)	0.149	0.72 (0.46–1.12)	0.027	0.67 (0.46–0.95)	0.027	0.65 (0.44–0.95)	4 × 10⁻⁵	0.51 (0.37–0.70)
Age at SCT >50 years	0.447	1.13 (0.82–1.57)	0.012	1.83 (1.14–2.94)	0.083	1.39 (0.96–2.00)	0.004	1.53 (1.15–2.05)	0.026	1.42 (1.04–1.93)	0.037	1.32 (1.02–1.71)
Interval diag. to SCT^a	0.465	1.05 (0.91–1.22)	0.209	1.00 (1.00–1.00)	0.974	1.00 (1.00–1.00)	0.461	1.00 (1.00–1.00)	0.410	1.00 (1.00–1.00)	0.717	1.00 (1.00–1.00)
Year of SCT	0.929	1.00 (1.00–1.00)	0.894	0.99 (0.87–1.30)	0.862	1.01 (0.91–1.12)	0.960	1.00 (0.92–1.09)	0.558	0.98 (0.90–1.06)	0.522	0.98 (0.91–1.05)
Secondary AML	0.033	1.68 (1.04–2.72)	0.232	1.55 (0.76–3.19)	0.434	1.26 (0.71–2.26)	0.192	1.35 (0.86–2.12)	0.163	1.40 (0.87–2.25)	0.058	1.47 (0.99–2.18)
Female D to male R	0.001	1.75 (1.27–2.43)	0.669	1.12 (0.66–1.90)	0.319	1.22 (0.82–1.82)	0.306	1.18 (0.86–1.62)	0.253	1.21 (0.87–1.69)	0.0004	1.62 (1.24–2.11)
R CMV seropositivity	0.231	1.32 (0.84–2.09)	0.851	0.93 (0.46–1.90)	0.733	0.91 (0.55–1.53)	0.651	0.91 (0.60–1.38)	0.456	0.85 (0.55–1.31)	0.639	0.92 (0.64–1.32)
D CMV seropositivity	0.417	1.17 (0.81–1.68)	0.241	1.49 (0.77–2.89)	0.812	1.06 (0.67–1.68)	0.358	1. 20 (0.82–1.75)	0.359	1.21 (0.81–1.80)	0.832	1.04 (0.75–1.42)
Center (frailty variable)	0.0007		0.047		0.211		0.917		0.913		0.154

AML acute myeloid leukemia, CMV cytomegalovirus, D donor, diag diagnosis, GRFS GVHD/relapse-free survival, GVHD graft-versus-host disease, LFS leukemia-free survival, NRM non-relapse mortality, OS overall survival, R recipient, SCT allogeneic stem cell transplantation

^aAnalyzed per 6-month interval